Jason Madore

Jason Madore

UNVERIFIED PROFILE

Are you Jason Madore?   Register this Author

Register author
Jason Madore

Jason Madore

Publications by authors named "Jason Madore"

Are you Jason Madore?   Register this Author

42Publications

1763Reads

12Profile Views

Timing of neoadjuvant immunotherapy in relation to surgery is crucial for outcome.

Oncoimmunology 2019 1;8(5):e1581530. Epub 2019 Mar 1.

Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Australia.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/2162402X.2019.1
Publisher Site
http://dx.doi.org/10.1080/2162402X.2019.1581530DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6492961PMC
March 2019

A Reduction in Inflammatory Macrophages May Contribute to Skin Cancer Chemoprevention by Nicotinamide.

J Invest Dermatol 2019 Feb 20;139(2):467-469. Epub 2018 Sep 20.

Dermatology, Sydney Cancer Centre, Bosch Institute, The University of Sydney and Royal Prince Alfred Hospital, Camperdown, Sydney, Australia; Melanoma Institute Australia, The University of Sydney, Sydney, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0022202X183258
Publisher Site
http://dx.doi.org/10.1016/j.jid.2018.08.018DOI Listing
February 2019

Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.

J Thorac Oncol 2017 09 16;12(9):1421-1433. Epub 2017 Jun 16.

Asbestos Diseases Research Institute, Sydney, Australia; Sydney Medical School, The University of Sydney, Sydney, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jtho.2017.05.024DOI Listing
September 2017

Targeting Adenosine in BRAF-Mutant Melanoma Reduces Tumor Growth and Metastasis.

Cancer Res 2017 09 26;77(17):4684-4696. Epub 2017 Jun 26.

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-17-0393DOI Listing
September 2017

Programmed cell death-ligand 1 expression in oral squamous cell carcinoma is associated with an inflammatory phenotype.

Pathology 2016 Oct 30;48(6):574-80. Epub 2016 Aug 30.

Sydney Medical School, The University of Sydney, Sydney, Australia; South West Clinical School, University of New South Wales, Sydney, Australia; Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2016.07.003DOI Listing
October 2016

PD-L1 Negative Status is Associated with Lower Mutation Burden, Differential Expression of Immune-Related Genes, and Worse Survival in Stage III Melanoma.

Clin Cancer Res 2016 08 9;22(15):3915-23. Epub 2016 Mar 9.

Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia. Sydney Medical School, The University of Sydney, Camperdown, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-1714DOI Listing
August 2016

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

Lung Cancer 2015 Aug 18;89(2):181-8. Epub 2015 May 18.

Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia; Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Melanoma Institute Australia, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2015.05.007DOI Listing
August 2015

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.

Pigment Cell Melanoma Res 2015 May 22;28(3):245-53. Epub 2014 Dec 22.

Melanoma Institute Australia, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pcmr.12340
Publisher Site
http://dx.doi.org/10.1111/pcmr.12340DOI Listing
May 2015

ID4 controls mammary stem cells and marks breast cancers with a stem cell-like phenotype.

Nat Commun 2015 Mar 27;6:6548. Epub 2015 Mar 27.

1] The Kinghorn Cancer Centre &Cancer Research Division, Garvan Institute of Medical Research, Darlinghurst, New South Wales 2010, Australia [2] St Vincent's Clinical School, Faculty of Medicine, UNSW, Kensington, New South Wales 2033, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms7548DOI Listing
March 2015

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Lancet Oncol 2013 Aug 9;14(9):853-62. Epub 2013 Jul 9.

Division of Epidemiology, Department of Health Research and Policy, Stanford University, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70253-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006367PMC
August 2013

Low expression of the X-linked ribosomal protein S4 in human serous epithelial ovarian cancer is associated with a poor prognosis.

BMC Cancer 2013 Jun 22;13:303. Epub 2013 Jun 22.

Centre de Recherche en Cancérologie de l'Université Laval, Hôpital Hôtel-Dieu de Québec, Quebec City, QC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-13-303DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708827PMC
June 2013

Crk adaptor proteins act as key signaling integrators for breast tumorigenesis.

Breast Cancer Res 2012 May 8;14(3):R74. Epub 2012 May 8.

Department of Biochemistry, McGill University, Rosalind and Morris Goodman Cancer Research Centre, 3655 Promenade Sir William Osler, Montréal, QC H3G 1Y6, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/bcr3183DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446336PMC
May 2012

H3K27 demethylation by JMJD3 at a poised enhancer of anti-apoptotic gene BCL2 determines ERα ligand dependency.

EMBO J 2011 Aug 12;30(19):3947-61. Epub 2011 Aug 12.

Département de Biologie, Faculté des Sciences, Université de Sherbrooke, Sherbrooke, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/emboj.2011.284DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3209777PMC
August 2011

Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.

J Pathol 2010 Feb;220(3):392-400

Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CHUM)/Institut du Cancer de Montréal, Montréal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.2659DOI Listing
February 2010

Characterization of three new serous epithelial ovarian cancer cell lines.

BMC Cancer 2008 May 28;8:152. Epub 2008 May 28.

Centre de recherche du Centre hospitalier de l'Université de Montréal/Institut du cancer de Montréal, Montreal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-8-152DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2467432PMC
May 2008

An apoptotic molecular network identified by microarray: on the TRAIL to new insights in epithelial ovarian cancer.

Cancer 2007 Jul;110(2):297-308

The Research Centre of the University of Montreal Teaching Hospital (CR-CHUM)/Montreal Cancer Institute, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.22812DOI Listing
July 2007

From gene profiling to diagnostic markers: IL-18 and FGF-2 complement CA125 as serum-based markers in epithelial ovarian cancer.

Int J Cancer 2006 Apr;118(7):1750-8

Centre de Recherche du Center Hospitalier de l'Université de Montréal (CR-CHUM), Institut du Cancer de Montréal, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ijc.21521DOI Listing
April 2006